Cancer News and Research

Latest Cancer News and Research

Pro-Pharmaceuticals closes $310,000 private placement tranche

Pro-Pharmaceuticals, Inc., today announced that it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.4 million.

4 May 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.

4 May 2010

Chances of surviving lung cancer much lower in England than in Norway or Sweden: Scientists

The chances of surviving lung cancer are much lower in England than they are in Norway or Sweden, scientists at King's College London have found.

4 May 2010

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

GTx, Inc. today reported financial results for the first quarter of 2010. The net income for the first quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009. Net income for the current period included the recognition of approximately $54.9 million in collaboration revenue due to the termination of our license and collaboration agreement with Merck & Co., Inc in March 2010.

4 May 2010

Celsion reports $4.6 million net loss from operations for first-quarter 2010

Celsion Corporation, a leading oncology drug development company, announced today financial results for the first quarter ended March 31, 2010 and addressed the progression of the clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox® is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.

4 May 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Each day in the United States, 482 people are diagnosed with a brain tumor. For these 482 people, not many treatments exist. With the current treatments available, only 5% of those diagnosed with a Glioblastoma Multiform will survive more than 5 years. Only two new treatments have been approved by the FDA in the past two decades.

4 May 2010

New study finds stereotypies in more than 60% of orphaned or abandoned children

Stereotypies -- repetitive behaviors such as rocking, flapping, spinning objects and head-banging – are commonly seen in people with autism or mental retardation. They can also be acquired by children exposed to severe neglect and deprivation, along with declines in IQ, mental health and language.

4 May 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Approval of personalized therapy for lung cancer in Europe will change way of treatment

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work, a leading expert said today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

4 May 2010

Consumer Reports Health lays out next steps for consumers in variety of situations

With health reform now the law of the land, Consumer Reports Health lays out next steps for consumers in a variety of situations - those who are currently insured; Medicare and Medicaid recipients; people with pre-existing conditions; parents of children with pre-existing conditions; parents of uninsured young adults; and people who develop serious illnesses.

4 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

MicroStockProfit.com releases investment report on Vical

MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Sunrise Senior Living reports net loss of $16.0M for first-quarter 2010

Sunrise Senior Living, Inc. today reported financial results and operating data for the first quarter of 2010. Sunrise will host a conference call and webcast Tuesday, May 4, 2010 at 8:00 a.m. ET, to discuss the financial results.

4 May 2010

Merci Retriever receives Shonin approval in Japan

Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the Merci Retriever, Merci Microcatheter, and Merci Balloon Guide Catheter have received Shonin approval in Japan.

4 May 2010

CBAI signs License and Cooperation agreement with AXM Pharma

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that an architectural firm has been retained for the new, 200,000 square foot umbilical cord blood processing and storage facility in China.

4 May 2010

Study comparing enteroscopy technologies finds SE quicker than DBE for examining small intestine

Spirus Medical, Inc., a leading developer of diagnostic and therapeutic advancement systems for gastroenterology, announced at Digestive Disease Week 2010 that results from the first-ever prospective study comparing enteroscopy technologies show spiral enteroscopy (SE) to be more than three times faster, on average, than double-balloon enteroscopy (DBE) in examining the small intestine.

4 May 2010

Shorter shifts for endoscopists positively influence polyp detection rates

A shorter daily shift schedule for endoscopists, the physicians who perform colonoscopies, avoids a decrease in the polyp detection rate as the day progresses, research from Mayo Clinic indicates. The findings, which have implications for endoscopist scheduling, were presented by Mayo Clinic investigators today at Digestive Disease Week 2010, (http://www.ddw.org/wmspage.cfm?parm1=679) the annual meeting of the American Gastroenterological Association.

4 May 2010

LA BioMed receives $1.5M in grant to study contraceptive for men

As the birth control pill marks its 50th birthday this month, Los Angeles Biomedical Research Institute announced today that it has received $1.5 million in grant funding to study a contraceptive for men that uses a combination of two hormonal gels applied to the skin of the arm and abdomen.

4 May 2010

Drive for expediency should not compromise care in breast cancer diagnosis, treatment

While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.

4 May 2010

National Cancer Institute data: San Francisco has highest rate of liver cancer in the nation

Recent data released from the National Cancer Institute confirms that San Francisco has the highest rate of liver cancer in the nation. The leading cause of liver cancer is hepatitis B.

4 May 2010

Cancer News and Research

Latest Cancer News and Research

Pro-Pharmaceuticals closes $310,000 private placement tranche

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Chances of surviving lung cancer much lower in England than in Norway or Sweden: Scientists

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

Celsion reports $4.6 million net loss from operations for first-quarter 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

New study finds stereotypies in more than 60% of orphaned or abandoned children

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Approval of personalized therapy for lung cancer in Europe will change way of treatment

Consumer Reports Health lays out next steps for consumers in variety of situations

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

MicroStockProfit.com releases investment report on Vical

Sunrise Senior Living reports net loss of $16.0M for first-quarter 2010

Merci Retriever receives Shonin approval in Japan

CBAI signs License and Cooperation agreement with AXM Pharma

Study comparing enteroscopy technologies finds SE quicker than DBE for examining small intestine

Shorter shifts for endoscopists positively influence polyp detection rates

LA BioMed receives $1.5M in grant to study contraceptive for men

Drive for expediency should not compromise care in breast cancer diagnosis, treatment

National Cancer Institute data: San Francisco has highest rate of liver cancer in the nation

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in